Alpha Cognition (OTC:ACOGF) Issues Earnings Results

Alpha Cognition (OTC:ACOGF) released its quarterly earnings results on Monday. The company reported C($0.01) earnings per share for the quarter, beating the consensus estimate of C($0.04) by C$0.03, Yahoo Finance reports.

Alpha Cognition Price Performance

Shares of ACOGF traded up C$0.02 on Tuesday, reaching C$0.46. The company’s stock had a trading volume of 19,119 shares, compared to its average volume of 74,791. The stock’s 50 day simple moving average is C$0.54 and its two-hundred day simple moving average is C$0.55. The stock has a market capitalization of C$54.38 million, a P/E ratio of -3.29 and a beta of 2.87. Alpha Cognition has a 12-month low of C$0.16 and a 12-month high of C$0.74.

Wall Street Analysts Forecast Growth

Separately, Raymond James raised Alpha Cognition from a “hold” rating to a “moderate buy” rating in a report on Monday, July 15th.

Alpha Cognition Company Profile

Alpha Cognition Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases.